Roche Holding stock holds steady as investors await fresh catalysts

Roche Holding AG (CH0012032048) remains a closely followed large-cap healthcare name, with its latest published figures still shaping the share story. The company reported 2025 sales of CHF 60.5 billion, and core EPS of CHF 18.03 for the year, while the proposed dividend for 2025 was raised to CHF 9.70 per share.

2025 numbers set the baseline

Roche said 2025 group sales were CHF 60.5 billion, with Diagnostics sales at CHF 14.1 billion and Pharmaceuticals sales at CHF 46.4 billion, giving investors a clear split between the two main divisions. Core EPS of CHF 18.03 for 2025 and the higher dividend proposal of CHF 9.70 per share show that cash generation and shareholder returns remain central to the investment case.

The comparison that matters most is the year-on-year base effect embedded in those 2025 figures: the company is being judged against a full-year sales base of CHF 60.5 billion and earnings power of CHF 18.03 per share. In the absence of a fresh market quote in the available search set, the latest audited report metrics provide the reference point for valuation and expectation-setting.

Sales mix still matters

Roche’s 2025 revenue mix stayed dominated by Pharmaceuticals at CHF 46.4 billion, which remained more than three times the CHF 14.1 billion posted by Diagnostics. That mix matters because the higher-margin drug business still carries most of the profit sensitivity, while Diagnostics provides scale and diversification.

For investors tracking Roche stock, the important question is how that split evolves through 2026, especially if newer product launches or volume trends shift the balance. The 2025 numbers give a concrete starting point: CHF 46.4 billion in Pharmaceuticals sales, CHF 14.1 billion in Diagnostics sales, and CHF 60.5 billion in group sales overall.

Dividend keeps the focus on cash

The proposed 2025 dividend of CHF 9.70 per share adds a second anchor for the story, because Roche has long used payout strength to support the equity case. With core EPS at CHF 18.03, the dividend level indicates a payout that still leaves room for reinvestment and balance-sheet flexibility.

That makes the stock less dependent on a single quarterly surprise and more on the durability of product demand, launch cadence, and operating discipline. The latest full-year figures therefore matter not only as history, but as the benchmark against which 2026 progress will be measured.

Ocrevus remains a key product

One of Roche’s most important products is Ocrevus, the multiple sclerosis therapy that remains a major contributor to the Pharmaceuticals division. In a group that generated CHF 46.4 billion of Pharmaceuticals sales in 2025, therapies of that scale help explain why the market keeps a close eye on product concentration and lifecycle management.

Product-level performance matters because Roche stock is not traded only on headline earnings. It is also priced on how well major medicines such as Ocrevus defend their revenue base against competition, patent pressure, and pipeline timing.

Market value as benchmark

With no live quote available in the current evidence set, Roche Holding stock is best framed against the reported 2025 operating base rather than a same-day price. The company’s CHF 60.5 billion in sales, CHF 18.03 in core EPS, and CHF 9.70 dividend proposal remain the clearest numerical markers for valuation work.

That leaves the next company update as the most relevant catalyst for a re-rating or a reset in expectations. Until then, the 2025 report numbers are the hard reference point for the share.

Read deeper

Roche Holding remains a large-cap Swiss healthcare group with a heavy pharmaceuticals mix and a payout story that continues to matter for long-term holders.